8-K: Harmony Biosciences Reports Record Q2 Revenue, Reaffirms Guidance

Harmony Biosciences announced preliminary record net product revenue of approximately $261 million for Q2 2026, a 30% year-over-year increase, and reaffirmed its full-year revenue guidance.

Summary

• Harmony Biosciences reported preliminary unaudited net product revenue of approximately $261 million for the second quarter of 2026.
• This represents a new quarterly revenue record, with a 30% year-over-year increase and a 21% sequential increase from Q1 2026.
• The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion.
• Chief Financial Officer Glenn Reicin stepped down effective July 16, 2026, to pursue other opportunities.
• Stephen Mollichella, SVP and Controller, has been appointed Interim Principal Financial Officer.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive filing due to record revenue, strong growth, and reaffirmed guidance, despite the CFO transition.

Positives

• Record quarterly net product revenue of approximately $261 million for Q2 2026.
• 30% year-over-year growth in net product revenue for Q2 2026.
• 21% sequential growth in net product revenue from Q1 2026 to Q2 2026.
• Reaffirmation of full-year 2026 net product revenue guidance between $1.0 billion and $1.04 billion.
• Continued strong demand for WAKIX and disciplined commercial execution.

Negatives

• Departure of the Chief Financial Officer, Glenn Reicin.

Risks

• The potential impact of known factors and the impossibility of anticipating all factors that could affect actual results.
• Risks and uncertainties discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 24, 2026.
• Commercialization efforts and strategy for WAKIX.
• Market acceptance and clinical utility of pitolisant in additional indications.
• Ability to expand license agreements.
• Availability of favorable insurance coverage and reimbursement for WAKIX.
• Competition in the industry.
• Failure to successfully execute growth strategy, including potential delays.

Future Outlook

The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, citing strong first-half performance and current business trends. Full Q2 2026 financial results and business updates are scheduled for August 4, 2026.

Management Comments

• "Our record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business," said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences.
• "Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in our ability to achieve full-year net revenue of $1.0 billion to $1.04 billion."
• Harmony thanks Mr. Reicin and wishes him well in his future endeavors.

Industry Context

StockSavvy.ai notes that Harmony Biosciences' strong preliminary Q2 revenue growth for WAKIX, a drug for rare neurological diseases, aligns with trends of increasing demand for specialized therapies in the biopharmaceutical sector. The reaffirmation of full-year guidance suggests continued market penetration and effective commercial strategies.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact from record revenue and reaffirmed guidance, potentially supporting stock price. CFO transition may introduce short-term uncertainty.
• Employees: Continued business momentum and financial leadership stability with an interim CFO.
• Customers: Continued access to WAKIX, with strong commercial execution ensuring supply.
• Suppliers: Continued demand for WAKIX likely means sustained business for suppliers.

Next Steps

• Report full second quarter 2026 financial results and provide a business update on August 4, 2026.
• Conduct a search for a permanent Chief Financial Officer.

Key Dates

Recommendation

The strong revenue performance and reaffirmed guidance are positive indicators. However, the departure of the CFO introduces a degree of uncertainty that warrants a 'hold' recommendation pending further clarity on the permanent CFO appointment and full Q2 results.

Keywords

Harmony Biosciences, WAKIX, net product revenue, Q2 2026, revenue guidance, CFO departure, interim CFO, pharmaceutical